StartsideATHA • NASDAQ
add
Athira Pharma Inc
Forrige sluttkurs
0,59 $
Dagsintervall
0,56 $ - 0,60 $
Årsintervall
0,41 $ - 4,30 $
Markedsverdi
21,74 mill. USD
Gjennomsnittlig volum
305,48k
P/E-tall
-
Utbytte
-
Hovedbørs
NASDAQ
Markedsnyheter
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
| (USD) | sep. 2024info | Endring år til år |
|---|---|---|
Omsetning | — | — |
Driftskostnader | 25,49 mill. | −27,25 % |
Nettoomsetning | −28,74 mill. | 12,83 % |
Netto resultatmargin | — | — |
Fortjeneste per aksje | — | — |
EBITDA | −25,25 mill. | 27,44 % |
Faktisk avgiftssats | — | — |
Balanseregnskap
Totale aktiva
Totale passiva
| (USD) | sep. 2024info | Endring år til år |
|---|---|---|
Kontant / kortsiktige inv. | 68,86 mill. | −60,19 % |
Totale aktiva | 86,25 mill. | −53,30 % |
Totale passiva | 28,66 mill. | −4,25 % |
Total egenkapital | 57,58 mill. | — |
Utestående aksjer | 38,67 mill. | — |
P/B-forhold | 0,40 | — |
Avkastning på aktiva | −64,54 % | — |
Avkastning på kapital | −88,74 % | — |
Kontantstrøm
Netto kontantstrøm
| (USD) | sep. 2024info | Endring år til år |
|---|---|---|
Nettoomsetning | −28,74 mill. | 12,83 % |
Kontantstrøm fra drift | −23,02 mill. | 4,01 % |
Kontanter fra investering | 18,04 mill. | −12,81 % |
Kontanter fra finansiering | 12,00k | — |
Netto kontantstrøm | −4,97 mill. | −50,94 % |
Fri kontantstrøm | −10,13 mill. | 13,86 % |
Om
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Grunnlagt
2011
Hovedkvarter
Nettsted
Ansatte
66
